Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nanozomal CBD+
- Development stage
- Unknown
- Lead developer
- Afrigen Biologics and Vaccines
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral
01
Overview
Nanozomal CBD+ is a health supplement developed by Afrigen Biologics, a subsidiary of Avacare Health Group. It utilizes a proprietary nanosomal and nanoemulsion encapsulation technology to significantly enhance the bioavailability of cannabidiol (CBD). By making the CBD water-soluble, the formulation allows for up to 15 times greater absorption into the bloodstream compared to traditional CBD oils, while also providing a faster onset of action. The product is marketed for its anti-inflammatory, antioxidant, and analgesic properties, and is used to address conditions such as anxiety, sleep disorders, and muscular tension. It is notable for being the first nanosomal product developed and manufactured on the African continent.
- Brand names
- Nanozomal CBD+Nanozomal CBD
- Other names
- Nanosomal cannabidiol
02
Targets
CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on Nanozomal CBD+.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanozomal CBD+.